http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Jul 2026 08:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jul+20/26811101.html si-local-file:///var/storage/secattach/20260724/26811101.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jul+20/26811101.html Fri, 24 Jul 2026 08:32:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jul+20/26811101.html si-local-file:///var/storage/secattach/20260724/26811101.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jul+20/26811101.html Fri, 24 Jul 2026 08:32:00 -0400 O.30973479 VIR http://www.streetinsider.com/Management+Changes/Vir+Biotechnology+names+interim+CFO+as+O%27Byrne+departs/26811073.html <p>Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its Chief Financial Officer, Jason O'Byrne, is leaving the company, with Brent Sabatini appointed as Interim Principal Financial Officer effective July 23, according to a press release.</p> <p>O'Byrne will remain with the company through August 3 to assist with the transition. Vir Biotechnology said it has begun a search for a permanent CFO.</p> <p>Sabatini has served as Senior Vice President and Chief Accounting Officer at Vir Biotechnology since February 2023. Before joining the company, he was Head of Finance at Capsida Biotherapeutics, Inc. and previously held roles at Amgen Inc. from 2004 to 2021, including http://www.streetinsider.com/Management+Changes/Vir+Biotechnology+names+interim+CFO+as+O%27Byrne+departs/26811073.html Fri, 24 Jul 2026 08:30:36 -0400 O.30973479 VIR http://www.streetinsider.com/Management+Changes/Vir+Biotechnology+names+interim+CFO+as+O%27Byrne+departs/26811073.html <p>Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its Chief Financial Officer, Jason O'Byrne, is leaving the company, with Brent Sabatini appointed as Interim Principal Financial Officer effective July 23, according to a press release.</p> <p>O'Byrne will remain with the company through August 3 to assist with the transition. Vir Biotechnology said it has begun a search for a permanent CFO.</p> <p>Sabatini has served as Senior Vice President and Chief Accounting Officer at Vir Biotechnology since February 2023. Before joining the company, he was Head of Finance at Capsida Biotherapeutics, Inc. and previously held roles at Amgen Inc. from 2004 to 2021, including http://www.streetinsider.com/Management+Changes/Vir+Biotechnology+names+interim+CFO+as+O%27Byrne+departs/26811073.html Fri, 24 Jul 2026 08:30:36 -0400 O.30973479 VIR http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Chief+Financial+Officer+Transition/26811061.html <p> SAN FRANCISCO--(BUSINESS WIRE)--</p> <p class="bwalignl">Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer.</p><p class="bwalignl">"Brent has deep institutional knowledge and financial acumen and has played a significant role in our strategic business development efforts and latest public offering, which helped to establish http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Chief+Financial+Officer+Transition/26811061.html Fri, 24 Jul 2026 08:30:00 -0400 O.30973479 VIR http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Chief+Financial+Officer+Transition/26811061.html <p> SAN FRANCISCO--(BUSINESS WIRE)--</p> <p class="bwalignl">Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer.</p><p class="bwalignl">"Brent has deep institutional knowledge and financial acumen and has played a significant role in our strategic business development efforts and latest public offering, which helped to establish http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Chief+Financial+Officer+Transition/26811061.html Fri, 24 Jul 2026 08:30:00 -0400 O.30973479 VIR http://www.streetinsider.com/Business+Wire/Vir+Biotechnology+Announces+Chief+Financial+Officer+Transition/26811061.html <p> SAN FRANCISCO--(BUSINESS WIRE)--</p> <p class="bwalignl">Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer.</p><p class="bwalignl">"Brent has deep institutional knowledge and financial acumen and has played a significant role in our strategic business development efforts and latest public offering, which helped to establish http://www.streetinsider.com/Business+Wire/Vir+Biotechnology+Announces+Chief+Financial+Officer+Transition/26811061.html Fri, 24 Jul 2026 08:30:00 -0400 O.30973479 VIR http://www.streetinsider.com/Business+Wire/Vir+Biotechnology+Announces+Chief+Financial+Officer+Transition/26811061.html <p> SAN FRANCISCO--(BUSINESS WIRE)--</p> <p class="bwalignl">Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer.</p><p class="bwalignl">"Brent has deep institutional knowledge and financial acumen and has played a significant role in our strategic business development efforts and latest public offering, which helped to establish http://www.streetinsider.com/Business+Wire/Vir+Biotechnology+Announces+Chief+Financial+Officer+Transition/26811061.html Fri, 24 Jul 2026 08:30:00 -0400 O.30973479 VIR http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+to+Host+Conference+Call+for+Second+Quarter+2026+Financial+Results/26801576.html <p> SAN FRANCISCO--(BUSINESS WIRE)--</p> <p class="bwalignl">Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.vir.bio%2Fevents-and-presentations%2Fdefault.aspx&amp;esheet=54575256&amp;newsitemid=20260722881739&amp;lan=en-US&amp;anchor=Events+%26+Presentations&amp;index=1&amp;md5=f6e68f53c73936677d10023106d6768e" shape="rect">Events &amp; Presentations</a> page of the Vir Biotechnology website.</p><p class="bwalignl"><b>About Vir Biotechnology</b></p><p class="bwalignl">Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+to+Host+Conference+Call+for+Second+Quarter+2026+Financial+Results/26801576.html Wed, 22 Jul 2026 16:05:00 -0400 O.30973479 VIR http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+to+Host+Conference+Call+for+Second+Quarter+2026+Financial+Results/26801576.html <p> SAN FRANCISCO--(BUSINESS WIRE)--</p> <p class="bwalignl">Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.vir.bio%2Fevents-and-presentations%2Fdefault.aspx&amp;esheet=54575256&amp;newsitemid=20260722881739&amp;lan=en-US&amp;anchor=Events+%26+Presentations&amp;index=1&amp;md5=f6e68f53c73936677d10023106d6768e" shape="rect">Events &amp; Presentations</a> page of the Vir Biotechnology website.</p><p class="bwalignl"><b>About Vir Biotechnology</b></p><p class="bwalignl">Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+to+Host+Conference+Call+for+Second+Quarter+2026+Financial+Results/26801576.html Wed, 22 Jul 2026 16:05:00 -0400 O.30973479 VIR http://www.streetinsider.com/Business+Wire/Vir+Biotechnology+to+Host+Conference+Call+for+Second+Quarter+2026+Financial+Results/26801576.html <p> SAN FRANCISCO--(BUSINESS WIRE)--</p> <p class="bwalignl">Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.vir.bio%2Fevents-and-presentations%2Fdefault.aspx&amp;esheet=54575256&amp;newsitemid=20260722881739&amp;lan=en-US&amp;anchor=Events+%26+Presentations&amp;index=1&amp;md5=f6e68f53c73936677d10023106d6768e" shape="rect">Events &amp; Presentations</a> page of the Vir Biotechnology website.</p><p class="bwalignl"><b>About Vir Biotechnology</b></p><p class="bwalignl">Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious http://www.streetinsider.com/Business+Wire/Vir+Biotechnology+to+Host+Conference+Call+for+Second+Quarter+2026+Financial+Results/26801576.html Wed, 22 Jul 2026 16:05:00 -0400 O.30973479 VIR http://www.streetinsider.com/Business+Wire/Vir+Biotechnology+to+Host+Conference+Call+for+Second+Quarter+2026+Financial+Results/26801576.html <p> SAN FRANCISCO--(BUSINESS WIRE)--</p> <p class="bwalignl">Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.vir.bio%2Fevents-and-presentations%2Fdefault.aspx&amp;esheet=54575256&amp;newsitemid=20260722881739&amp;lan=en-US&amp;anchor=Events+%26+Presentations&amp;index=1&amp;md5=f6e68f53c73936677d10023106d6768e" shape="rect">Events &amp; Presentations</a> page of the Vir Biotechnology website.</p><p class="bwalignl"><b>About Vir Biotechnology</b></p><p class="bwalignl">Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious http://www.streetinsider.com/Business+Wire/Vir+Biotechnology+to+Host+Conference+Call+for+Second+Quarter+2026+Financial+Results/26801576.html Wed, 22 Jul 2026 16:05:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vir+Biotechnology%2C+Inc.++++++++++++++++Filed+by%3A+Ramasastry+Saira/26705884.html si-local-file:///var/storage/secattach/20260629/26705884.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vir+Biotechnology%2C+Inc.++++++++++++++++Filed+by%3A+Ramasastry+Saira/26705884.html Mon, 29 Jun 2026 15:07:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vir+Biotechnology%2C+Inc.++++++++++++++++Filed+by%3A+Ramasastry+Saira/26705884.html si-local-file:///var/storage/secattach/20260629/26705884.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vir+Biotechnology%2C+Inc.++++++++++++++++Filed+by%3A+Ramasastry+Saira/26705884.html Mon, 29 Jun 2026 15:07:00 -0400 O.30973479 VIR http://www.streetinsider.com/Analyst+PT+Change/Vir+Biotechnology+%28VIR%29+PT+Raised+to+%2427+at+Morgan+Stanley/26633016.html Morgan Stanley analyst Michael Ulz raised the price target on Vir Biotechnology (NASDAQ: VIR) to $27.00 (from $23.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Vir+Biotechnology+%28VIR%29+PT+Raised+to+%2427+at+Morgan+Stanley/26633016.html Thu, 11 Jun 2026 08:24:05 -0400 VIR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631123.html si-local-file:///var/storage/secattach/20260610/26631123.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631123.html Wed, 10 Jun 2026 18:21:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631123.html si-local-file:///var/storage/secattach/20260610/26631123.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631123.html Wed, 10 Jun 2026 18:21:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631122.html si-local-file:///var/storage/secattach/20260610/26631122.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631122.html Wed, 10 Jun 2026 18:20:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631122.html si-local-file:///var/storage/secattach/20260610/26631122.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631122.html Wed, 10 Jun 2026 18:20:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09/26630265.html si-local-file:///var/storage/secattach/20260610/26630265.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09/26630265.html Wed, 10 Jun 2026 16:27:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09/26630265.html si-local-file:///var/storage/secattach/20260610/26630265.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09/26630265.html Wed, 10 Jun 2026 16:27:00 -0400 O.30973479 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR